代表性论文
1. Kong T#, Du P#, Ma R#, Wang H#, Ma X, Lu J, Gao Z, Qi H, Li R, Zhang H, Xia F, Liu Y, Wang R, Duan K, Wang Z, Wang Q*, Gao GF*. Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virus. EBioMedicine. 2024, 109:105392.
2. Zhao R#, Wu L#, Sun J#, Liu D#, Han P, Gao Y, Zhang Y, Xu Y, Qu X, Wang H, Chai Y, Chen Z, Gao GF, Wang Q*. Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections. Nat Commun. 2024, 15(1): 4660.
3. Hu S#, Wu C#, Wu X#, Ma X, Shu C, Chen Q, Zheng A, Yang H, Lu J*, Du P*, Gao GF*, Wang Q*. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities. Sci Bull (Beijing). 2023, 68(23): 3003-3012.
4. Wu L#, Zheng A#, Tang Y#, Chai Y#, Chen J, Cheng L, Hu Y, Qu J, Lei W, Liu WJ, Wu G, Zeng S, Yang H*, Wang Q*, Gao GF*. A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery. Sci China Life Sci. 2023, 66(10): 2201-2213.
5. Liu H#, Wu L#, Liu B#, Xu K#, Lei W#, Deng J#, Rong X, Du P, Wang L, Wang D, Zhang X, Su C, Fan Z, Bi Y, Chen H, Liu WJ, Qi J, Cui Q, Qi S, Fan R*, Jiang J*, Wu G*, Gao GF*, Wang Q*. Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. Cell Rep Med. 2023, 4(2): 100918.
6. Huang M#, Wu L#, Zheng A#, Xie Y#, He Q#, Rong X, Han P, Du P, Han P, Zhang Z, Zhao R, Jia Y, Li L, Bai B, Hu Z, Hu S, Niu S, Hu Y, Liu H, Liu B, Cui K, Li W, Zhao X, Liu K, Qi J*, Wang Q*, Gao GF*. Atlas of currently-available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. Immunity. 2022, 55(8):1501-1514.
7. Zheng A#, Wu L#, Ma R#, Han P#, Huang B, Qiao C, Wang Q*, Tan W*, Gao GF*, Han P*. A binding-enhanced but enzymatic activity-eliminated human ACE2 efficiently neutralizes SARS-CoV-2 variants. Signal Transduct Target Ther. 2022, 7(1):10.
8. Niu S#, Wang J#, Bai B, Wu L, Zheng A, Chen Q, Du P, Han P, Zhang Y, Jia Y, Qiao C, Qi J, Tian W*, Wang H*, Wang Q*, Gao GF*. Molecular basis of cross-species ACE2 interactions with SARS-CoV-2-like viruses of pangolin origin. EMBO J (Cover story). 2021, 40(16): e107786.
9. Liu K#, Pan X#, Li L#, Yu F#, Zheng A, Du P, Han P, Meng Y, Zhang Y, Wu L, Chen Q, Song C, Jia Y, Niu S, Lu D, Qiao C, Chen Z, Ma D, Ma X, Tan S, Zhao X, Qi J*, Gao GF*, Wang Q*. Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. Cell. 2021, 184(13): 3438-3451.e10.
10. Liu K#, Tan S#, Niu S#, Wang J#, Wu L, Sun H, Zhang Y, Pan x, Qu X, Meng Y, Jia Y, Chen Q, Deng C, Yan J, Wang H-W, Wang Q*, Qi J*, Gao GF*. Cross-species recognition of SARS-CoV-2 to bat ACE2. Proc Natl Acad Sci U S A. 2021, 118(1): e2020216118.
11. Wu L#, Chen Q#, Liu K#, Wang J#, Han P, Zhang Y, Hu Y, Meng Y, Pan X, Qiao C, Tian S, Du P, Song H, Shi W, Qi J, Wang HW*, Yan J*, George, F. G, Wang Q*. Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. Cell Discov. 2020, 6: 68.
12. Sun H#, Li Y#, Liu P#, Qiao C, Wang X, Wu L, Liu K, Hu Y, Su C, Tan S, Zou S, Wu G*, Yan J, Gao GF, Qi J* and Wang Q*. Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. Emerg Microbes Infect. 2020, 9(1): 1238-1241.
13. Shi R#, Shan C#, Duan X#, Chen Z#, Liu P#, Song J#, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z, Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang FS*, Wang Q*, Gao GF*, Yuan Z* and Yan J*. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. 2020, 584(7819): 120-124.
14. Wang Q#, Zhang Y#, Wu L#, Niu S#, Song C#, Zhang Z, Lu G, Qiao C, Hu Y, Yuen K-Y, Wang QS, Zhou H, Yan J* and Qi J*. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020, 181(4): 894-904.e9.
15. Wang Q*#, Song H#, Cheng H, Qi J, Nam G, Tan S, Wang J, Fang M, Shi Y, Tian Z, Cao X, An Z, Yan J, Gao GF*. Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cell Mol Immunol. 2020, 17(9) 966-975.
16. Wang Q#, Ma T#, Wu Y#, Chen Z#, Zeng H, Tong Z, Gao F, Qi J, Zhao Z, Chai Y, Yang H, Wong G, Bi Y, Wu L, Shi R, Yang M, Song J, Jiang H, An Z, Wang J, Yilma TD, Shi Y, Liu WJ, Liang M, Qin C, Gao GF*, Yan J*. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nat Microbiol. 2019, 4(7): 1231-1241.
代表性图片
HCoV-19 RBD结合受体ACE2的整体结构与分子作用网络
代表性授权专利
1. 痘病毒多抗原嵌合疫苗及其用途（发明专利），授权号：ZL202211537702.4
